News

Radiation proctitis (RP) is a significant unmet medical need, with no well-established standard of care. Access is actively seeking marketing partners globally for ProctiGard™. Access Pharmaceuticals president and

Lemtrada is supported by a clinical development program that involved about 1,500 patients and 5,400 patient-years of follow-up. The approval in Brazil follows the recent approvals of Lemtrada

The company said that if approved, empagliflozin will be marketed under the name Jardiance. Empagliflozin belongs to the SGLT2 inhibitor class of drugs that targets glucose directly and

The decision to return the rights of tozadenant has been made on the assessment of UCB’s early and late stage clinical development pipeline as well as its preclinical

The European Medicines Agency’s (EMA) CHMP has issued positive opinions for the conditional marketing authorizations of Vynfinit, Folcepri and Neocepri to treat adult patients with folate receptor-positive, platinum-resistant,

This satisfies the necessary patient numbers proposed for the trial. Following from the positive results achieved from the interim analysis of the serum Insulin-like Growth Factor-I (sIGF-I) data

Medivir CEO Maris Hartmanis said: "The recommendation is one additional step in the global strategy that our partner Janssen has for simeprevir, to offer a new and efficacious

According to the recommendation, Bexsero should be routinely used in infants from two months of age to help protect against meningococcal serogroup B (meningitis B). The implementation will

NCCN ORP vice president Dr Diane E. Paul noted it is grateful to collaborate with Boehringer Ingelheim on this ground-breaking research initiative. "The research supported by this grant